Effect of gastric acid‐reducing agents on the pharmacokinetics and efficacy of lemborexant

• Autores principales: Ishani Landry (Autor), Jagadeesh Aluri (Autor), Nancy Hall (Autor), Dinesh Kumar (Autor), Satish Dayal (Autor), Margaret Moline (Autor), Larisa Reyderman (Autor)
• Formato: Libro
• Publicado: Wiley, 2020-12-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Abstract Lemborexant is a dual orexin receptor antagonist approved for treating insomnia. As the solubility of lemborexant is pH‐sensitive, the impact of the gastric acid‐reducing agent (ARA), famotidine, on lemborexant pharmacokinetics was evaluated in a Phase 1 study. Additionally, post hoc analys...